{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Sotatercept: New Therapies for PAH","description":" Pulmonary arterial hypertension (PAH)&amp;nbsp;remains&amp;nbsp;a devastating, progressive disease with high morbidity and mortality despite advances in targeted therapies.&amp;nbsp;Sotatercept, the most recent addition to the PAH treatment landscape, has&amp;nbsp;demonstrated&amp;nbsp;robust efficacy across multiple phase 3 randomized clinical trials. The HYPERION trial expands the evidence base by showing a favorable benefit\u2013risk profile for&amp;nbsp;sotatercept&amp;nbsp;when used early in the disease course. Pooled analyses across trials further suggest that&amp;nbsp;sotatercept&amp;nbsp;may have a meaningful impact on mortality in patients with PAH.&amp;nbsp;   In this interview,&amp;nbsp;Mary Norine Walsh MD, MACC&amp;nbsp;and&amp;nbsp;Vallerie V. McLaughlin, MD, FACC&amp;nbsp;discuss the\u202fphase 3 HYPERION trial.\u202f&amp;nbsp;  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40744700\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/200485780"}